Diagnosis and treatment of therapy-related acute myeloid leukemia.
Strickland SA, Vey N.
Crit Rev Oncol Hematol. 2022 Mar;171:103607. doi: 10.1016/j.critrevonc.2022.103607. Epub 2022 Jan 31.
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, Narayanan D, Ouseph MM, Kurzer JH, Hasserjian RP.
Blood Adv. 2022 May 10;6(9):2847-2853. doi: 10.1182/bloodadvances.2021006239.
Progress toward Better Treatment of Therapy-Related AML.
Kotsiafti A, Giannakas K, Christoforou P, Liapis K.
Cancers (Basel). 2023 Mar 8;15(6):1658. doi: 10.3390/cancers15061658.
Clonal Hematopoiesis and therapy related MDS/AML.
Desai P, Roboz GJ.
Best Pract Res Clin Haematol. 2019 Mar;32(1):13-23. doi: 10.1016/j.beha.2019.02.006. Epub 2019 Feb 15.
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, Coats T, Nagumantry S, Hodgson K, Whitmill R, Amott I, Flynn G, Taussig D, Zhao R, Cunningham N, Roset M, Cuadras D, Medalla G, Kuter H, Park S, Legg A, Khan AB.
Br J Haematol. 2024 Oct;205(4):1326-1336. doi: 10.1111/bjh.19622. Epub 2024 Jul 8.
Therapy-related myeloid neoplasms.
Ganser A, Heuser M.
Curr Opin Hematol. 2017 Mar;24(2):152-158. doi: 10.1097/MOH.0000000000000316.
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.
Gross S, Ihlow J, Busack L, Adamiak K, Schrezenmeier J, Jesse J, Schwarz M, Flörcken A, Vuong LG, Rieger K, Krönke J, le Coutre P, Boldt V, von Brünneck AC, Horst D, Burmeister T, Blau IW, Keller U, Bullinger L, Westermann J.
Blood Cancer J. 2024 Sep 16;14(1):160. doi: 10.1038/s41408-024-01140-5.
NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
Falini B.
Am J Hematol. 2023 Sep;98(9):1452-1464. doi: 10.1002/ajh.26989. Epub 2023 Jun 15.
Therapy related AML in a case of chronic lymphocytic leukemia.
Gajendra S, Jha B, Sharma R.
Am J Blood Res. 2023 Apr 15;13(2):77-83. eCollection 2023.
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, Lamprecht TL, Shen D, Hundal J, Fulton RS, Heath S, Baty JD, Klco JM, Ding L, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Graubert TA, Ley TJ, Druley T, Link DC, Wilson RK.
Nature. 2015 Feb 26;518(7540):552-555. doi: 10.1038/nature13968. Epub 2014 Dec 8.
